ikarovec

Ikarovec Limited is a UK-based biotechnology company focused on developing novel bicistronic gene therapies for chronic eye diseases, particularly in the field of ophthalmology.

Founded in 2018 and headquartered at the Norwich Research Park, Ikarovec aims to enhance long-term sight preservation by providing a single injection that delivers continuous therapeutic effects, reducing the need for repetitive treatments. The company is advancing an early-stage pipeline of AAV-based gene therapies targeting conditions such as Geographic Atrophy, Wet Age-Related Macular Degeneration, and Diabetic Macular Edema. Ikarovec's proprietary platform allows for the expression of two therapeutic proteins from a single vector, addressing multiple disease pathways simultaneously. Their innovative approach is designed to meet the needs of patients suffering from chronic retinal degenerative diseases, ultimately aiming to improve their quality of life by minimizing treatment burdens.